AI
| Followers | 21 |
| Posts | 2457 |
| Boards Moderated | 1 |
| Alias Born | 09/01/2009 |
Tuesday, August 26, 2014 1:02:10 PM
ONCS Chart:
Market Value1 $105,087,024 a/o Aug 25, 2014
Shares Outstanding 244,388,427 a/o Jun 09, 2014
Float Not Available
Authorized Shares Not Available
Par Value 0.001
SAN DIEGO --(BUSINESS WIRE)-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $16 million of securities in a registered direct offering. OncoSec has agreed to sell to such investors an aggregate of 22,535,212 shares of its common stock at a price of $0.71 per share. Additionally, investors will receive warrants to purchase up to an aggregate of 7,887,325 shares of common stock at an exercise price of $0.90 per share for a term of five years.
Market Value1 $105,087,024 a/o Aug 25, 2014
Shares Outstanding 244,388,427 a/o Jun 09, 2014
Float Not Available
Authorized Shares Not Available
Par Value 0.001
SAN DIEGO --(BUSINESS WIRE)-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $16 million of securities in a registered direct offering. OncoSec has agreed to sell to such investors an aggregate of 22,535,212 shares of its common stock at a price of $0.71 per share. Additionally, investors will receive warrants to purchase up to an aggregate of 7,887,325 shares of common stock at an exercise price of $0.90 per share for a term of five years.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
